TGTX (TG Therapeutics, Inc.) Stock Financials & Earnings

TGTXTG Therapeutics, Inc.

Mkt Cap$5B

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$616M

Net Income (TTM)$447M

EPS (TTM)$2.77

Free Cash Flow (TTM)-$25M

Gross Margin83.6%

Op. Margin20.0%

Net Margin72.6%

FCF Margin-4.1%

P/S Ratio (TTM)7.6x

P/E Ratio (TTM)10.4x

YoY Rev Growth+87.3%

Employees—

Earnings Reports

▶Q4 2025NEW

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases....

CEO Michael S. WeissIPO May 3, 2010www.tgtherapeutics.com

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$8M	$7M	-$37M
Q2 23	$16M	$14M	-$45M
Q3 23	$166M	$162M	$115M
Q4 23	$44M	$36M	-$12M
Q1 24	$63M	$58M	-$9M
Q2 24	$73M	$65M	$9M
Q3 24	$84M	$75M	$12M
Q4 24	$108M	$93M	$30M
Q1 25	$121M	$105M	$9M
Q2 25	$141M	$122M	$35M
Q3 25	$162M	$134M	$29M
Q4 25	$193M	$154M	$50M

Revenue Breakdown

Valuation

Quarter	P/S	P/E
Q1 23	273.6x	—
Q2 23	135.1x	—
Q3 23	6.2x	—
Q4 23	13.3x	245.8x
Q1 24	7.4x	51.9x
Q2 24	7.6x	27.5x
Q3 24	12.8x	—
Q4 24	13.9x	195.4x
Q1 25	15.0x	147.8x
Q2 25	11.5x	86.6x
Q3 25	10.1x	12.0x
Q4 25	7.2x	9.9x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$60M	-$60M
Q2 23	-$42M	-$42M
Q3 23	$84M	$84M
Q4 23	-$13M	-$13M
Q1 24	-$8M	-$8M
Q2 24	$6M	$6M
Q3 24	-$12M	-$12M
Q4 24	-$26M	-$26M
Q1 25	-$29M	-$29M
Q2 25	$7M	$7M
Q3 25	-$23M	-$23M
Q4 25	$20M	$20M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$24K
Q4 24	$21K
Q1 25	$25K
Q2 25	$42K
Q3 25	$80K
Q4 25	$67K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	+287.1%	-35.0%
Q2 23	+2606.1%	+53.7%
Q3 23	+176298.9%	+45.6%
Q4 23	+54863.8%	+8.3%
Q1 24	+713.5%	+62.4%
Q2 24	+357.0%	+6.4%
Q3 24	-49.4%	+40.0%
Q4 24	+146.0%	+38.6%
Q1 25	+90.4%	+54.3%
Q2 25	+92.1%	+64.4%
Q3 25	+92.8%	+85.2%
Q4 25	+78.0%	+81.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$7M	87.4%
Q2 23	$13M	78.0%
Q3 23	$9M	5.5%
Q4 23	$9M	21.3%
Q1 24	$9M	14.7%
Q2 24	$9M	12.9%
Q3 24	$12M	14.0%
Q4 24	$12M	11.0%
Q1 25	$15M	12.4%
Q2 25	$16M	11.6%
Q3 25	$18M	10.9%
Q4 25	$16M	8.1%

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 23	$16M	$28M	—
Q2 23	$22M	$36M	—
Q3 23	$15M	$33M	—
Q4 23	$17M	$34M	—
Q1 24	$33M	$35M	—
Q2 24	$18M	$39M	—
Q3 24	$20M	$42M	—
Q4 24	$24M	$39M	—
Q1 25	$46M	$50M	—
Q2 25	$32M	$56M	—
Q3 25	$41M	$63M	—
Q4 25	$41M	—	$63M

Revenue Segments

Quarter	License revenue	Product revenue, net	License	Product	License Revenue	Milestone	Other Revenue	Royalty
Q1 23	$38K	$8M	—	—	—	—	—	—
Q2 23	$38K	$16M	—	—	—	—	—	—
Q3 23	—	—	$141M	$25M	—	—	—	—
Q1 24	—	—	—	$50M	$38K	$13M	$415K	$33K
Q2 24	—	—	—	$73M	$38K	—	$682K	$150K
Q3 24	—	—	—	$83M	$38K	—	$315K	$229K
Q1 25	—	—	—	$120M	$38K	—	$558K	$605K
Q2 25	—	—	—	$139M	$2M	—	—	—
Q3 25	—	—	—	$159M	$2M	—	—	—
Q4 25	—	—	—	$189M	—	—	$3M	$5M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$61M	$78M	$140M
Q2 23	$97M	$48M	$145M
Q3 23	$151M	$78M	$229M
Q4 23	$93M	$125M	$218M
Q1 24	$75M	$134M	$210M
Q2 24	$83M	$134M	$217M
Q3 24	$196M	$145M	$341M
Q4 24	$180M	$131M	$311M
Q1 25	$132M	$144M	$276M
Q2 25	$129M	$123M	$252M
Q3 25	$74M	$58M	$132M
Q4 25	$79M	$63M	$142M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	140M	+2.3%
Q2 23	142M	+0.8%
Q3 23	156M	+10.2%
Q4 23	143M	-8.2%
Q1 24	146M	+2.2%
Q2 24	159M	+9.0%
Q3 24	161M	+0.8%
Q4 24	160M	-0.3%
Q1 25	163M	+1.6%
Q2 25	163M	-0.1%
Q3 25	161M	-1.0%
Q4 25	159M	-1.0%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$6K	24
FY 15	$3K	44
FY 16	$2K	64
FY 17	$2K	75
FY 18	$1K	105
FY 19	$1K	134
FY 20	$559	272
FY 21	$23K	286
FY 22	$12K	226
FY 23	$885K	264
FY 24	$973K	338
FY 25	$616	1.0M